Financial writer recommends Voyager Therapeutics, Inc. for high-risk investors due to promising preclinical Alzheimer's ...

Neurocrine Biosciences begins phase 3 registrational study of osavampator as an adjunctive therapy to treat major depressive disorder: San Diego Wednesday, January 29, 2025, 18:00 ...

Neurocrine Biosciences, Inc., is a leading neuroscience-focused, biopharmaceutical company, announced it has amended its agreement with Takeda to develop and commercialize osavampator (NBI-1065845/TAK ...

Neurocrine Biosciences, Inc. (NASDAQ:NBIX) amended its agreement with Takeda Pharmaceutical Co Ltd (NYSE:TAK) to develop and ...

USA-based Neurocrine Biosciences yesterday revealed it has amended its agreement with Japanese pharma major Takeda to develop ...

Neurocrine Biosciences Inc. (NASDAQ:NBIX) shares, currently trading at $148.19, maintained a positive outlook as Stifel ...

Little information has emerged about osavampator, a potentially first-in-class drug, since its promising Phase II performance ...

Stifel Nicolaus analyst Paul Matteis has maintained their bullish stance on NBIX stock, giving a Buy rating on January 24.Invest with ...

Takeda is taking back the home license for a phase 3-stage depression drug as part of an amendment to its multi-asset ...

An announcement from Neurocrine ( ($NBIX) ) is now available. On January 24, 2025, Neurocrine Biosciences announced an amendment to its Exclusive ...

Brown & Brown's fourth-quarter revenue beat analyst expectations as commissions and fees rose. The insurance company said profit fell to $210 million from $269 million a year earlier, though adjusted ...

Neurocrine Biosciences amended its agreement with Takeda Pharmaceutical regarding the development and commercialization of osavampator, a treatment for major depressive disorder.